Correction: Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma - Yao Liang; Osamu Maeda; Chiaki Kondo; Kazuki Nishida; Yuichi Ando (PLoS ONE, 2025)